Towards arresting type 1 diabetes: Breaking results of the MELD-ATG & Ver-A-T1D trials

Exploring disease-modifying therapies and precision medicine in type 1 diabetes

Watch the full video on YouTube to explore the latest findings from two major clinical trials investigating disease-modifying therapies for type 1 diabetes.

In this episode, Prof. Chantal Mathieu (KU Leuven, endocrinologist and leading researcher in type 1 diabetes) and Prof. Francesco Dotta (University of Siena, expert in type 1 diabetes pathophysiology and clinical trials) discuss the MELD-ATG and VERA-T1D trials conducted through the European INNODIA consortium.

Topics include:

• The goals of the INNODIA consortium and its role in advancing type 1 diabetes research
• The VERA-T1D trial, testing verapamil as a potential beta-cell protective therapy
• Why the trial narrowly missed its primary endpoint but still provides important clinical insights
• The MELD-ATG adaptive trial, identifying a low-dose immunotherapy that can delay beta-cell decline
• How innovative trial designs allow researchers to optimise dosing strategies
• The importance of biomarkers and precision medicine approaches in type 1 diabetes

Explore the latest EASD Annual Meeting presentations and learn more about our expert speakers:

1. Prof. Chantal Mathieu
2. Prof. Francesco Dotta

For more expert conversations, explore our podcast archive.